This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the National Infusion Center of America (NICA).

ACKNOWLEDGEMENT

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

LIVE DATE OF RELEASE

Thursday, September 1, 2022, from 1:30-2:30pm ET.

TARGET AUDIENCE

The target audiences for the HCP activity are lipidologists, cardiologists, endocrinologists, and primary care physicians

STATEMENT OF NEED/PROGRAM OVERVIEW

Patients with homozygous familial hypercholesterolemia (HoFH) are at very high risk for atherosclerotic cardiovascular disease (ASCVD). Early diagnosis, genetic testing, and therapeutic selection are key to achieving lipid-reduction goals. However, patient-specific barriers, combined with other systemic healthcare barriers, hinder the identification of probable cases, limit screening, and delay treatment initiation.

To help overcome these barriers, join a panel of expert cardiologists to review the signs, exam findings, and family histories that suggest the presence of HoFH. Real patient stories will help illustrate the frustrations and obstacles patients face on the way to a diagnosis of HoFH. Expert panelists will then share strategies and tools to enhance patient access to infused medications, apply current guidelines, and identify those patients who can most benefit from newer approved and investigational agents that promise to reduce LDL-C and other lipid particles in patients with HoFH.

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

• Combine clinical history, exam findings, family history, and LDL-C levels to diagnose HoFH earlier
• Develop strategies to address patient barriers and attitudes related to the diagnosis and management of HoFH
• Identify the place of newer agents with novel mechanisms of action in the management of HoFH, while reducing the need for apheresis in adults and children
• Demonstrate an ability to educate patients on strategies to enhance access to infused therapies for HoFH, including referrals and locating an infusion center

PHYSICIAN ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 60 minutes to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Name of Faculty or Presenter	Reported Financial Relationship
Christie M. Ballantyne, MD, FACP, FACC Chief, Section of Cardiology Chief, Section of Cardiovascular Research Professor of Medicine Baylor College of Medicine	Grant/Research Support- All significant. (All paid to institution, not individual): Abbott Diagnostic, Akcea, Amgen, Arrowhead, Esperion, Ionis, Merck, Novartis, Novo Nordisk, Regeneron, Roche Diagnostic Consulting Fee (e.g., Advisory Board - 89Bio, Abbott Diagnostics, Alnylam Pharmaceuticals, Althera, Amarin, Amgen, Arrowhead, Astra Zeneca, Denka Seiken, Esperion, Genentech, Gilead, Illumina, Matinas BioPharma Inc, Merck, New Amsterdam, Novartis, Novo Nordisk, Pfizer, Regeneron, Roche Diagnostic, Sanofi-Synthelabo
Jorge Plutzky M.D. Director, Preventive Cardiology Brigham and Women's Hospital	Consulting Fee (e.g., Advisory Board): Alnylam Altimmune, Amgen, Esperion (Clinical trial steering committee), Merck, MJ Health Lifesciences, Novo Nordisk Contracted Research: Boehringer Ingelheim Novo Nordisk
Chelsea Reimer Patient Panelist	Nothing to disclose

The planners and managers have the following relevant financial relationships with ineligible companies:

Name of Planner	Reported Financial Relationship
Lindsay Borvansky	Nothing to disclose
Andrea Funk	Nothing to disclose
Liddy Knight	Nothing to disclose
Ashley Cann	Nothing to disclose
Lauren Sinclair	Nothing to disclose
Carole Drexel	Nothing to disclose
Colleen Hefner	Nothing to disclose
Caroline Laurendeau	Nothing to disclose
Valerie Harrell-Patient Participant	Nothing to disclose

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com

Technical Support:

For any technical issues or issues with your CME Certificate, please contact CardioCareLive at 877-394-1306 or at Support@CardioCareLive.com .

---